This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
Notice.
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 20 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Approval is withdrawn as of November 19, 2018.
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. ( printed page 53069)
| Application No. | Drug | Applicant |
|---|---|---|
| NDA 006002 | Aralen Hydrochloride (chloroquine hydrochloride (HCl)) Injection, Equivalent to (EQ) 40 milligram (mg) base/milliliter (mL); Aralen (chloroquine phosphate) Tablets, EQ 300 mg base | Sanofi-Aventis, U.S., LLC, 55 Corporate Dr., Bridgewater, NJ 08807. |
| NDA 008107 | Leucovorin calcium for Injection USP, EQ 60 mg base/vial for solution, oral; EQ 3 mg base/mL injection; EQ 50 mg base/vial injection; EQ 100 mg base/vial injection; EQ 350 mg base/vial injection | Hospira Inc., Subsidiary of Pfizer Inc., 235 East 42nd St., New York, NY 10017. |
| NDA 009321 | Cholografin Meglumine (iodipamide meglumine) Injection, 10.3% and 52% (cholografin sodium, 20%) | Bracco Diagnostics, Inc., 259 Prospect Plains Rd., Monroe Township, NJ 08831. |
| NDA 017566 | Brevicon (ethinyl estradiol; norethindrone) Tablets, 0.035 mg/0.5 mg (21-Day Regimen) | Allergan Pharmaceuticals International, Ltd., c/o Allergan Sales, LLC, 2525 Dupont Dr., Irvine, CA 92612. |
| NDA 018181 | Mycelex (clotrimazole) Topical Solution, 1% | Bayer HealthCare LLC, 100 Bayer Blvd., 100 Bayer Rd., Pittsburgh, PA 15205. |
| NDA 018182 | Mycelex-7 (clotrimazole) Tablets, 100 mg | Do. |
| NDA 018183 | Mycelex (clotrimazole) Topical Cream, 1% | Do. |
| NDA 018230 | Mycelex-7 (clotrimazole) Topical Vaginal Cream, 1% | Do. |
| NDA 018856 | D-Xylose (xylose) Powder, 25 grams (g)/bottle | Lyne Laboratories, 10 Burke Dr., Brockton, MA 02301. |
| NDA 018874 | Calcijex (calcitriol) Injection, 0.001 mg/mL and 0.002 mg/mL | AbbVie, Inc., 1 North Waukegan Rd., North Chicago, IL 60064. |
| NDA 020214 | Zemuron (rocronium bromide) Injection, 50 mg/5 mL (10 mg/mL); 10 mg/mL (10 mg/mL); 100 mg/10 mL (10 mg/mL) | Organon USA Inc., Subsidiary of Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033. |
| NDA 020389 | Mycelex-7 Combination Pack (clotrimazole) Topical Vaginal Cream and Tablets, 1%, 100 mg | Bayer HealthCare LLC. |
| NDA 020528 | Mavik (trandolapril) Tablets, 1 mg, 2 mg, and 4 mg | AbbVie, Inc. |
| NDA 020738 | Teveten (eprosartan mesylate) Tablets, 300 mg, 400 mg, and 600 mg | Do. |
| NDA 020863 | Pletal (cilostazol) Tablets, 50 mg and 100 mg | Otsuka Pharmaceutical Development and Commercialization, Subsidiary of Otsuka Pharmaceutical Company, Ltd., 2440 Research Blvd., Rockville, MD 20850. |
| NDA 021268 | Teveten HCT (eprosartan mesylate and hydrochlorothiazide) Tablets, 600/12.5 mg and 600/25 mg | AbbVie, Inc. |
| NDA 021410 | Avandamet (rosiglitazone maleate and metformin hydrochloride (HCl)) Tablets, 500 mg EQ 1 mg base; 500 mg EQ 2 mg base; 500 mg EQ 4 mg base; 1 g EQ 2 mg base; 1 g EQ 4 mg base | GlaxoSmithKline, 1250 South Collegeville Rd., Collegeville, PA 19426. |
| NDA 021511 | Copegus (ribavirin) Tablets, 200 mg and 400 mg | Hoffmann La-Roche, Inc., Subsidiary of Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. |
| NDA 021700 | Avandaryl (glimepiride and rosiglitazone maleate) Tablets, 1 mg/4 mg; 2 mg/4 mg; 2 mg/8 mg; 4 mg/4 mg; 4 mg/8 mg | SB Pharmco Puerto Rico Inc., Subsidiary of GlaxoSmithKline, 1250 South Collegeville Rd., Collegeville, PA 19426. |
| NDA 205123 | Olysio (simeprevir sodium) Capsules, EQ 150 mg base | Janssen Pharmaceuticals, Inc., 1000 U.S. Rte. 202 South, Raritan, NJ 08869. |
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of November 19, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on November 19, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Dated: October 15, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-22805 Filed 10-18-18; 8:45 am]
BILLING CODE 4164-01-P